Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Issue 4 (2nd October 2018)

• Record Type: Journal Article
• Authors: Henry, Christopher; Zaizafoun, Manaf; Stock, Eileen; Ghamande, Shekhar; Arroliga, Alejandro C.; White, Heath D.
• Is Part Of: Proceedings. Volume 31:Issue 4(2018)
• Page Start: 419
• Page End: 423
• Publication Date: 2018-10-02
• Subjects: ACE inhibitors -- statins -- viral pneumonia; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2018.1499293
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: Angiotensin-converting enzyme (ACE) inhibitors and statins may potentially benefit patients with viral infections and pneumonia. Our study aimed to evaluate the impact of ACE inhibitors and statins on the rates of intubation and death in viral pneumonia. We retrospectively studied 1055 adult patients admitted to a tertiary care center in central Texas with a positive respiratory viral polymerase chain reaction test. Of these, 539 had clinical presentation and imaging consistent with pneumonia. We collected information on demographic characteristics, microbiology, comorbid conditions, medication use, and outcomes. ACE inhibitors given prior to admission were associated with an increased risk of death or intubation (odds ratio [OR] = 3.02; 95% confidence interval [CI], 1.30–7.01), whereas statin use prior to admission did not change rates of death or intubation. Lower rates of death and intubation were noted with continued use of ACE inhibitors (OR =0.25; 95% CI, 0.09–0.64) and statins (OR =0.26; 95% CI, 0.08–0.81) throughout the hospital stay. We added further evidence of the beneficial effect of continued use of ACE inhibitors and statins in viral pneumonia.